NASDAQ:GRFS - GRIFOLS S A/S Stock Price, News, & Analysis

Get Started

$20.53 -0.16 (-0.77 %)

(As of 11/21/2018 03:43 PM ET)

Previous Close$20.69

Today's Range$20.52 - $20.95

52-Week Range$17.47 - $25.18

Volume101,507 shs

Average Volume1.46 million shs

Market Capitalization$14.70 billion

P/E Ratio18.90

Dividend Yield1.79%

Beta1.18

Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:GRFS

Previous Symbol

CUSIPN/A

Webwww.grifols.com

Phone34-93-571-2200

Debt

Debt-to-Equity Ratio1.47

Current Ratio2.78

Quick Ratio1.07

Price-To-Earnings

Trailing P/E Ratio18.90

Forward P/E Ratio17.55

P/E Growth1.55

Sales & Book Value

Annual Sales$4.88 billion

Price / Sales2.87

Cash Flow$1.3816 per share

Price / Cash14.86

Book Value$7.06 per share

Price / Book2.91

Profitability

EPS (Most Recent Fiscal Year)$1.10

Net Income$749.04 million

Net Margins16.55%

Return on Equity18.32%

Return on Assets6.24%

Miscellaneous

Employees18,296

Outstanding Shares682,820,000

Market Cap$14.70 billion

OptionableOptionable

GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions

What is GRIFOLS S A/S's stock symbol?

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S?

GRIFOLS S A/S announced a special dividend on Thursday, November 8th. Stockholders of record on Monday, December 3rd will be given a dividend of $0.2283 per share on Tuesday, December 11th. This represents a dividend yield of 2.25%. The ex-dividend date is Friday, November 30th. This is a positive change from GRIFOLS S A/S's previous special dividend of $0.01. View GRIFOLS S A/S's Dividend History.

When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work?

Shares of GRIFOLS S A/S split on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were payable to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

When is GRIFOLS S A/S's next earnings date?

GRIFOLS S A/S is scheduled to release their next quarterly earnings announcement on Thursday, November 22nd 2018. View Earnings Estimates for GRIFOLS S A/S.

What price target have analysts set for GRFS?

7 analysts have issued 12 month price targets for GRIFOLS S A/S's shares. Their predictions range from $20.00 to $20.00. On average, they anticipate GRIFOLS S A/S's share price to reach $20.00 in the next twelve months. This suggests that the stock has a possible downside of 2.6%. View Analyst Price Targets for GRIFOLS S A/S.

What is the consensus analysts' recommendation for GRIFOLS S A/S?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GRIFOLS S A/S.

Has GRIFOLS S A/S been receiving favorable news coverage?

Headlines about GRFS stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. GRIFOLS S A/S earned a coverage optimism score of 0.7 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days.

Are investors shorting GRIFOLS S A/S?

GRIFOLS S A/S saw a drop in short interest in October. As of October 15th, there was short interest totalling 2,944,231 shares, a drop of 37.6% from the September 28th total of 4,715,453 shares. Based on an average trading volume of 2,309,790 shares, the short-interest ratio is currently 1.3 days. View GRIFOLS S A/S's Current Options Chain.

Who are some of GRIFOLS S A/S's key competitors?

Some companies that are related to GRIFOLS S A/S include Shire (SHPG), Allergan (AGN), Celgene (CELG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO) and Bausch Health Companies (BHC).

Who are GRIFOLS S A/S's key executives?

GRIFOLS S A/S's management team includes the folowing people:

Mr. Raimon Grifols Roura, Co-Chief Exec. Officer & Exec. Director (Age 54)
Mr. Ramón Riera Roca, COO, Chief Commercial Officer & Exec. Director (Age 63)
Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 62)
Mr. Víctor Grifols Deu, Co-CEO & Exec. Director (Age 41)
Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 60)

Who are GRIFOLS S A/S's major shareholders?

GRIFOLS S A/S's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (2.02%), AKO Capital LLP (1.44%), Credit Suisse AG (1.30%), Pictet Asset Management Ltd. (0.91%), Bank of New York Mellon Corp (0.72%) and Capital Research Global Investors (0.70%).

Which institutional investors are selling GRIFOLS S A/S stock?

GRFS stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., JPMorgan Chase & Co., JPMorgan Chase & Co., FIL Ltd, Credit Suisse AG, AKO Capital LLP, Capital Research Global Investors and Gladstone Capital Management LLP.

Which institutional investors are buying GRIFOLS S A/S stock?

GRFS stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, First Trust Advisors LP, Morgan Stanley, Envestnet Asset Management Inc., Banco de Sabadell S.A, Pictet Asset Management Ltd., Lenox Wealth Management Inc. and Vaughan Nelson Investment Management L.P..

How do I buy shares of GRIFOLS S A/S?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GRIFOLS S A/S's stock price today?

One share of GRFS stock can currently be purchased for approximately $20.53.

How big of a company is GRIFOLS S A/S?

GRIFOLS S A/S has a market capitalization of $14.70 billion and generates $4.88 billion in revenue each year. The biotechnology company earns $749.04 million in net income (profit) each year or $1.10 on an earnings per share basis. GRIFOLS S A/S employs 18,296 workers across the globe.

What is GRIFOLS S A/S's official website?

The official website for GRIFOLS S A/S is http://www.grifols.com.

How can I contact GRIFOLS S A/S?

GRIFOLS S A/S's mailing address is AVINGUDA DE LA GENERALITAT 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-2200 or via email at [email protected]

MarketBeat Community Rating for GRIFOLS S A/S (NASDAQ GRFS)

Community Ranking:		2.2 out of 5 ( )
Outperform Votes:		217 (Vote Outperform)
Underperform Votes:		270 (Vote Underperform)
Total Votes:		487

MarketBeat's community ratings are surveys of what our community members think about GRIFOLS S A/S and other stocks. Vote "Outperform" if you believe GRFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRFS will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 11/21/2018 by MarketBeat.com Staff

Featured Article: Book Value Per Share – BVPS